Angiogenic proteins as markers for predicting preeclampsia

References

• Villar J, Say L, Gulmezoglu M et al. Eclampsia and preeclampsia: a worldwide health problem for 2000 years. In: Preeclampsia. RCOG Press, London, UK, 189–207 (2003).
   Google Scholar
• Newman RB, Eddy GL. Association of eclampsia and hydatidiform mole: case report and review of the literature. Obstet. Gynecol. Surv. 43(4), 185–190 (1988).
   PubMedGoogle Scholar
• Brittain PC, Bayliss P. Partial hydatidiform molar pregnancy presenting with severe preeclampsia prior to twenty weeks gestation: a case report and review of the literature. Mil. Med. 160(1), 42–44 (1995).
   PubMedGoogle Scholar
• Roberts JM. Endothelial dysfunction in preeclampsia. Semin. Reprod. Endocrinol. 16(1), 5–15 (1998).
   PubMedGoogle Scholar
• Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet. Gynecol. 104(6), 1367–1391 (2004).
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88(5), 2348–2351 (2003).
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111(5), 707–716 (2003).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am. J. Obstet. Gynecol. 191(4), 1240–1246 (2004).
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190(6), 1541–1547; discussion 1547–1550 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95(9), 884–891 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmed A. Heparin – binding Angiogenic growth factors in pregnancy. Trophoblast Res. 10, 215–258 (1997).
   Google Scholar
• Ahmad S, Ahmed A. Regulation of soluble VEGFR-1 by VEGF and oxygen and its elevation in preeclampsia and fetal growth restriction. Placenta 22, 790–793 (2001).
   Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226(2), 324–328 (1996).
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12(6), 642–649 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou Y, McMaster M, Woo K et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am. J. Pathol. 160(4), 1405–1423 (2002).
   PubMed Web of Science ®Google Scholar
• Tsatsaris V, Goffin F, Munaut C et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metab. 88(11), 5555–5563 (2003).
   PubMed Web of Science ®Google Scholar
• Hirashima C, Ohkuchi A, Arai F et al. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens. Res. 28(9), 727–732 (2005).
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J. Clin. Endocrinol. Metab. 90(8), 4895–4903 (2005).
   PubMed Web of Science ®Google Scholar
• Buhimschi CS, Norwitz ER, Funai E et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 192(3), 734–741 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Thadhani R, Qian C et al. Urinary placental growth factor and risk of preeclampsia. JAMA 293(1), 77–85 (2005).
   PubMed Web of Science ®Google Scholar
• Aggarwal PK, Jain V, Sakhuja V, Karumanchi SA, Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int. 69(3), 621–624 (2006).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355(10), 992–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Hertig A, Berkane N, Lefevre G et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin. Chem. 50(9), 1702–1703 (2004).
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern. Fetal. Neonatal Med. 17(1), 3–18 (2005).
   PubMed Web of Science ®Google Scholar
• Wathen KA, Tuutti E, Stenman UH et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metab. 91(1), 180–184 (2006).
   PubMed Web of Science ®Google Scholar
• Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindhiemer M. Mapping the theories of Preeclampsia:the role of Placental Growth Factor and soluble fms-like tyrosine kinase 1. Obstet. Gynecol. (In press) (2007).
   PubMedGoogle Scholar